Patents by Inventor Zhigang C. Wang

Zhigang C. Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for predicting anti-cancer response
    Patent number: 10577662
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 3, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation, The Technical University of Denmark
    Inventors: Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • METHODS FOR PREDICTING ANTI-CANCER RESPONSE
    Publication number: 20170037478
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC., CHILDREN'S MEDICAL CENTER CORPORATION, THE TECHNICAL UNIVERSITY OF DENMARK
    Inventors: Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • Methods for predicting anti-cancer response
    Patent number: 9512485
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: December 6, 2016
    Assignees: Dana-Farber Cancer Institute. Inc., The Brigham and Women's Hospital. Inc., Children's Medical Center Corporation, The Technical University of Denmark
    Inventors: Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • METHOD OF DETERMINING CANCER PROGNOSIS
    Publication number: 20150292033
    Abstract: Provided is a method of predicting the prognosis of a patient with ovarian cancer by determining the total number of somatic exome mutations per genome (Nmut) and status of the BRCA1 and/or BRCA2 in the subject.
    Type: Application
    Filed: April 9, 2015
    Publication date: October 15, 2015
    Inventors: Zhigang C. Wang, James Dirk Iglehart, Andrea L. Richardson, Zoltan Szallasi, Nicolai Juul Birbak, Ursula Matulonis
  • Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
    Publication number: 20120052079
    Abstract: The present invention is based, in part, on the discovery that amplification of human chromosome 8q22-23 regions and over-expression of 8q22-23 genes (e.g., LAPTM4B and YWHAZ) is associated with and predictive of resistance to anthracycline-type chemotherapy. Accordingly, the invention relates to compositions, kits, and methods for predicting the response of cancer cells, e.g., breast, prostate, lung, ovarian, pancreatic, liver, and colon malignancies to anthracyclines.
    Type: Application
    Filed: August 10, 2011
    Publication date: March 1, 2012
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Andrea L. Richardson, Zhigang C. Wang
  • Variants of IL-1 beta gene and CD46 gene for diagnosing unexplained recurrent pregnancy loss
    Publication number: 20030032022
    Abstract: The discovery of an association between two variants of the human interleukin-1 gene (IL1B) beta promoter region and a variant of the CD46 gene intron 1 and T-helper type 1 immunity in unexplained recurrent pregnancy loss (URPL) is disclosed. These two IL1B variants are characterized by a base C at position-511 (IL1B-511C) and a base T at position-31 (IL1B-31T) from the transcriptional start site of the IL1B gene. The CD46 gene intron 1 variant is characterized by a change in the HindIII site in this intron. These IL1B promoter variants and CD46 gene intron 1 variants, and reagents for detecting said variants, are useful as diagnostic markers for the diagnosis and management of recurrent pregnancy loss. Accordingly, the invention provides methods and compositions which identify these variants for determining a subject's propensity for having reproductive failure and, particularly, reproductive failure attributed to Th1 cytokines.
    Type: Application
    Filed: September 12, 2001
    Publication date: February 13, 2003
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Joseph A. Hill, Zhigang C. Wang, Deborah Anderson, Edmond J. Yunis